卫宁健康(300253) - 2021 Q3 - 季度财报

Financial Performance - Revenue for Q3 2021 reached ¥738,591,239.57, an increase of 27.77% year-over-year[3] - Net profit attributable to shareholders was ¥148,060,378.06, reflecting a 15.03% increase compared to the same period last year[3] - The company reported a basic earnings per share of ¥0.0719, up 18.06% year-over-year[3] - For the first nine months of 2021, the company achieved operating revenue of CNY 1,762.97 million, a year-on-year increase of 28.56%[23] - The net profit attributable to shareholders for the same period was CNY 259.72 million, reflecting a year-on-year growth of 27.71%[23] - Net profit for the current period was ¥240,347,670.86, compared to ¥197,309,532.20 in the previous period, reflecting a growth of 21.8%[54] - Earnings per share (basic) increased to ¥0.1218 from ¥0.0962, representing a 26.1% rise[54] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,894,309,490.40, representing a 13.82% increase from the end of the previous year[3] - The company's total current assets as of September 30, 2021, amounted to 3,799,423,742.66 RMB, an increase from 3,235,331,436.47 RMB as of December 31, 2020[41] - The company's total assets reached 6,894,309,490.40 RMB as of September 30, 2021, compared to 6,057,147,858.20 RMB at the end of 2020[44] - Total liabilities amounted to ¥1,907,993,918.74, compared to ¥1,342,908,093.38 in the previous period, showing a growth of 42%[47] - Total current liabilities were reported at ¥1,229.27 billion, indicating a stable position[72] Cash Flow - Cash flow from operating activities showed a net outflow of ¥250,615,004.14, a 30.38% decrease compared to the previous year[3] - Operating cash inflow totaled CNY 1,520,788,754.07, an increase from CNY 1,137,137,874.14 in the previous period[59] - Operating cash outflow amounted to CNY 1,771,403,758.21, compared to CNY 1,329,353,416.10 last year[59] - Net cash flow from operating activities was CNY -250,615,004.14, worsening from CNY -192,215,541.96[59] - Cash inflow from financing activities reached CNY 1,040,742,355.97, significantly higher than CNY 340,453,254.04 last year[62] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 70,336[12] - The total number of shares held by the controlling shareholders, Zhou Wei and Wang Ying, is 423,802,370, accounting for 19.78% of the total share capital[15] - Liu Ning and associated parties hold a total of 140,627,616 shares, representing 6.56% of the total share capital[18] - The company has seen significant shareholder activity, with multiple private equity funds involved in shareholding agreements[15] - The overall shareholder structure reflects a mix of individual and institutional investors, enhancing market stability[15] Business Operations - The company's core medical health information business revenue accounted for 86.08% of total revenue, with a year-on-year growth of 13.57%[23] - The internet medical health business revenue surged by 636.14%, increasing its share of total revenue to 13.90%[23] - The WiNEX product has been implemented in approximately 140 hospitals nationwide, supporting the digital transformation of public hospitals[23] - The company signed multiple contracts for smart hospital projects, with several contracts exceeding CNY 10 million[23] - The "Nari Health" platform completed over 900,000 paid online consultation orders and over 1 million paid health management service orders in the first nine months of 2021[27] Financial Management - Operating costs increased by 37.42% year-over-year, primarily due to the consolidation of a new subsidiary, Lunyue Technology[10] - The company experienced a 375.34% increase in financial expenses due to interest accrued on convertible bonds[10] - Research and development expenses for the current period were ¥173,190,397.55, compared to ¥160,631,518.43 in the previous period, reflecting a 7.3% increase[52] - Financial expenses increased to ¥17,984,021.77 from ¥3,783,437.11, indicating a significant rise in costs[52] Investment Activities - The cumulative investment in the "New Generation Smart Medical Product Development and Cloud Service Project" was 21,461.89 million RMB, achieving an investment progress of 43.80%[37] - The cumulative investment in the "Marketing Network Expansion Project" was 6,864.63 million RMB, with an investment progress of 52.70%[37] - The total amount of convertible bonds issued by the company was 970,265,000.00 RMB, with a net amount raised of 961,209,622.64 RMB after deducting issuance costs[36] Regulatory and Compliance - The company is actively managing its share structure, with a focus on compliance with regulatory requirements regarding restricted shares[19] - The company decided to terminate the major asset restructuring plan with Chuangye Huikang Technology Co., Ltd. on July 24, 2021[40] - The company has not audited its third-quarter report, indicating a focus on internal assessments[73]